Skip to Main Content

Author Details

Fadi Brimo
McGill University Health Centre, McGill University
2007
156
32
PMIDPaper TitleJournal TitlePublished Year
36343786UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways.Cancer Lett2023
37717923Nested and Large Nested Subtypes of Urothelial Carcinoma of the Upper Urinary Tract: A Multi-institutional Study.Mod Pathol2023
38020525Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy.Eur Urol Open Sci2023
37680023ABCC2 brush-border expression predicts outcome in papillary renal cell carcinoma: a multi-institutional study of 254 cases.Histopathology2023
37126232Multimodal Biomarkers That Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance.J Urol2023
37073437Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression.J Pathol Clin Res2023
37037938A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients.Br J Cancer2023
36562104A Sarcomatoid Renal Cell Carcinoma with Clear Cell Papillary-Like Primary Tumor and Lymph Node Metastasis: A Diagnostic Conundrum.Int J Surg Pathol2023
35901948The Rate of Prostatic Involvement in Men Treated With Radical Cystectomy for Muscle Invasive Bladder Cancer.Pract Radiat Oncol2023
34728788Correction to: Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases.Mod Pathol2022
35411033Fatty acid oxidation enzyme ο3, ο2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients.Oncogene2022
35490858Morphologic alterations post trimodal therapy in muscle-invasive urothelial carcinoma: understanding the impact of post-treatment changes on the pathological interpretation and their potential clinical correlates.Hum Pathol2022
35900850Clinicopathologic Spectrum of Secondary Solid Tumors of the Prostate of Nonurothelial Origin: Multi-institutional Evaluation of 85 Cases.Am J Surg Pathol2022
36353066Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy.Eur Urol Open Sci2022
34949766Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients.Mod Pathol2022
34958810ABCC2 expression in papillary renal cell carcinoma provides better prognostic stratification than WHO/ISUP nucleolar grade.Hum Pathol2022
34862117Impact of sarcopenia on outcomes of patients treated with trimodal therapy for muscle invasive bladder cancer.Urol Oncol2022
34521993Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases.Mod Pathol2022
32948433Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey.Urol Oncol2021
33620995Erectile function after partial penectomy for penile cancer.Int Braz J Urol2021
35099374Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version.Can Urol Assoc J2021
35098169Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy.Eur Urol Open Sci2021
34611304Correction to: Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases.Mod Pathol2021
34830979Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma.Cancers (Basel)2021
33938798Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text.Can Urol Assoc J2021
34128484The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers.Adv Anat Pathol2021
34128483The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia.Adv Anat Pathol2021
33986291Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer.Nat Commun2021
33283758Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: Is post-treatment tumor bed biopsy always necessary?Urol Oncol2021
33421558Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer.Int J Radiat Oncol Biol Phys2021
33071190Evidence-based diagnostic accuracy measurement in urine cytology using likelihood ratios.J Am Soc Cytopathol2021
32589068The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.Arch Pathol Lab Med2021
32453694Continuing towards optimization of bladder cancer care in Canada: Summary of the third Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.Can Urol Assoc J2020
31915958Dataset for the reporting of carcinoma of the bladder-cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR).Virchows Arch2020
31821734Do we need PD-L1 as a biomarker for thyroid cytologic and histologic specimens?Cancer Cytopathol2020
32763409Design and Development of a Fully Synthetic Multiplex Ligation-Dependent Probe Amplification-Based Probe Mix for Detection of Copy Number Alterations in Prostate Cancer Formalin-Fixed, Paraffin-Embedded Tissue Samples.J Mol Diagn2020
32568842Metastatic Prostatic Adenocarcinoma in Patient With Muir-Torre Syndrome Misdiagnosed as Metastatic Sebaceous Carcinoma: Case Report and Systematic Literature Review.Am J Dermatopathol2020
30467243Revitalising an academic pathology department: lessons learnt.J Clin Pathol2019
30218308SIU-ICUD on bladder cancer: pathology.World J Urol2019
30140035The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy.Mod Pathol2019
30113732Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer.BJU Int2019
30136199The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer.World J Urol2019
31381885Integrated Molecular Analysis of Papillary Renal Cell Carcinoma and Precursor Lesions Unfolds Evolutionary Process from Kidney Progenitor-Like Cells.Am J Pathol2019
31433512A three-gene DNA methylation biomarker accurately classifies early stage prostate cancer.Prostate2019
31231128Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma.Mod Pathol2019
31340802Improving ultrasound-based prostate volume estimation.BMC Urol2019
31192862Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureter-Nephroureterectomy and Ureterectomy Specimens: Recommendations From the International Collaboration on Cancer Reporting (ICCR).Am J Surg Pathol2019
31009090Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR).Histopathology2019
31002177High-grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex.Histopathology2019
28753789Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.Eur Urol Focus2018
  • 1 - 50 of 156

Recommended Authors

Yale School of Medicine
Career Start Year 2015
Number of shared co-authors 2
University of Toronto
Career Start Year 2013
Number of shared co-authors 18
H. Lee Moffitt Cancer Center and Research Institute
Career Start Year 2013
Number of shared co-authors 8
Institut Curie, CNRS, PSL Research University
Career Start Year 2013
Number of shared co-authors 7
University of Michigan Medical School ann arbor
Career Start Year 2012
Number of shared co-authors 13
Royal Marsden NHS Foundation Trust
Career Start Year 2011
Number of shared co-authors 5
INSERM, Universite Clermont Auvergne
Career Start Year 2008
Number of shared co-authors 6
Mount Sinai Hospital, University of Toronto, University Health Network
Career Start Year 2007
Number of shared co-authors 11
Centre hospitalier de l'Universite de Montreal
Career Start Year 2006
Number of shared co-authors 16
University of Washington Medical Center
Career Start Year 2005
Number of shared co-authors 7
University of Florida
Career Start Year 2005
Number of shared co-authors 0
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 7
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year 2003
Number of shared co-authors 13
Yale School of Medicine
Career Start Year 2003
Number of shared co-authors 7
NIHR Oxford Biomedical Research Centre
Career Start Year 2002
Number of shared co-authors 9
Asan Medical Center, University of Ulsan College of Medicine
Career Start Year 2002
Number of shared co-authors 1
Samsung Medical Center, Sungkyunkwan University School of Medicine
Career Start Year 2000
Number of shared co-authors 0
Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Career Start Year 2000
Number of shared co-authors 22
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1997
Number of shared co-authors 8
University of Michigan ann arbor
Career Start Year 1997
Number of shared co-authors 18
H. Lee Moffitt Cancer Center and Research Institute
Career Start Year 1996
Number of shared co-authors 5
Memorial Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 6
Clinic of Gastroenterology, Vilnius University
Career Start Year 1995
Number of shared co-authors 1
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 10
New York-Presbyterian Hospital
Career Start Year 1994
Number of shared co-authors 14
Georgetown University
Career Start Year 1993
Number of shared co-authors 0
University of Colorado School of Medicine
Career Start Year 1991
Number of shared co-authors 14
University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU)
Career Start Year 1989
Number of shared co-authors 6
The Institute of Cancer Research
Career Start Year 1977
Number of shared co-authors 6
University of Texas MD Anderson Cancer Center
Career Start Year 1975
Number of shared co-authors 10

Collaborators

McGill University Health Centre, McGill University
Co-authored papers 55
McGill University Health Centre, McGill University
Co-authored papers 21
Research Institute of the McGill University Health Center (RI-MUHC)
Co-authored papers 19
University of Montreal Health Center
Co-authored papers 11
Queen's University
Co-authored papers 10
Centre Hospitalier de l'Universite de Montreal
Co-authored papers 9
CHU de Quebec-Universite Laval
Co-authored papers 9
McGill University and the Research Institute of the McGill University Health Centre
Co-authored papers 8
University Health Network, University of Toronto
Co-authored papers 8
Institute of Pathology, Friedrich-Alexander University Erlangen-Nurnberg (FAU)
Co-authored papers 7
Memorial Sloan Kettering Cancer Center
Co-authored papers 7
University of Toronto
Co-authored papers 7
Emory University School of Medicine
Co-authored papers 7
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Co-authored papers 6
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Co-authored papers 6
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 6
University of Toronto
Co-authored papers 5
Princess Margaret Cancer Center, University Health Network.
Co-authored papers 5
Michigan Center for Translational Pathology.
Co-authored papers 5
Queen's University
Co-authored papers 5
University of Edinburgh
Co-authored papers 5
University of Western Ontario
Co-authored papers 5
University of Toronto
Co-authored papers 5
Centre de Recherche du CHU de Quebec-Universite Laval (axe Oncologie)
Co-authored papers 4
University Health Network, Princess Margaret Cancer Center, University of Toronto
Co-authored papers 4
Princess Margaret Cancer Centre, University Health Network and University of Toronto
Co-authored papers 4
Sandra and Edward Meyer Cancer Center
Co-authored papers 4
University of Washington School of Medicine
Co-authored papers 4
CHU de Quebec-Universite Laval
Co-authored papers 4
Yale University School of Medicine
Co-authored papers 4